Cancer cell and microenvironmental rewiring by ADAR1 loss impairs glioblastoma tumor growth and extends survival
Cell Reports · 2025-09 · 44 (9) · 116151
DOI: 10.1016/j.celrep.2025.116151 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2025-09. Verfasst von Ángel F Álvarez-Prado und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, University of Lausanne, Lausanne, Switzerland; Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switze…. Hauptthemen laut MEDLINE: Adenosine Deaminase, Glioblastoma, Tumor Microenvironment, RNA-Binding Proteins. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EU Framework Programme for Research and Innovation Marie Skłodowska-Curie Actions, Brain Tumor Charity, European Molecular Biology Organization.
Abstract (Originalsprache)
Glioblastomas are the most frequent and aggressive primary brain tumors. Current treatments invariably fail, a consequence of the pronounced heterogeneity and plasticity of glioblastoma cells, as well as the contribution of an immunosuppressive microenvironment that promotes tumor progression and resistance to therapy. Here, we exploited an innate immunity checkpoint, RNA sensing, to simultaneously target cancer cells and their supporting microenvironment. Using various immunocompetent mouse models of glioblastoma, we found that genetic deletion of adenosine deaminase acting on RNA 1 (Adar1), a key regulator of the RNA-sensing pathway, resulted in significantly reduced tumor growth and prolonged survival. Mechanistically, these effects were mediated by two processes: cancer-cell-intrinsic responses and reprogramming of the immune microenvironment that fostered a pro-inflammatory, anti-tumoral state via type I interferon signaling. These findings establish proof of concept for the therapeutic potential of targeting ADAR1 in glioblastoma, offering new strategies for the treatment of this aggressive disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, University of Lausanne, Lausanne, Switzerland; Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland; Agora Cancer Research Centre Lausanne, 1011 Lausanne, Switzerla…
Förderung
- EU Framework Programme for Research and Innovation Marie Skłodowska-Curie Actions
- Brain Tumor Charity
- European Molecular Biology Organization
- Cancer Research Foundation Switzerland
- Ludwig Institute for Cancer Research Ltd
- Université de Lausanne
Zitieren
APA
Álvarez-Prado, Á. F., Hernández-Barranco, A., Rentsch, L., Costa, C. F., & Joyce, J. A. (2025). Cancer cell and microenvironmental rewiring by ADAR1 loss impairs glioblastoma tumor growth and extends survival. Cell Reports, 44(9), 116151. https://doi.org/10.1016/j.celrep.2025.116151
Vancouver
Álvarez-Prado ÁF, Hernández-Barranco A, Rentsch L, Costa CF, Joyce JA. Cancer cell and microenvironmental rewiring by ADAR1 loss impairs glioblastoma tumor growth and extends survival. Cell Reports. 2025;44(9):116151. doi:10.1016/j.celrep.2025.116151
BibTeX
@article{lvarezPrado2025,
author = {Álvarez-Prado, Ángel F and Hernández-Barranco, Alberto and Rentsch, Livia and Costa, Catia F and Joyce, Johanna A},
title = {Cancer cell and microenvironmental rewiring by ADAR1 loss impairs glioblastoma tumor growth and extends survival},
journal = {Cell Reports},
year = {2025},
volume = {44},
number = {9},
pages = {116151},
doi = {10.1016/j.celrep.2025.116151}
}
EUVIMED